GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eris Lifesciences Ltd (BOM:540596) » Definitions » EV-to-EBITDA

Eris Lifesciences (BOM:540596) EV-to-EBITDA : 19.08 (As of May. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Eris Lifesciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Eris Lifesciences's enterprise value is ₹133,293 Mil. Eris Lifesciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₹6,986 Mil. Therefore, Eris Lifesciences's EV-to-EBITDA for today is 19.08.

The historical rank and industry rank for Eris Lifesciences's EV-to-EBITDA or its related term are showing as below:

BOM:540596' s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.88   Med: 19.11   Max: 34.48
Current: 19.08

During the past 12 years, the highest EV-to-EBITDA of Eris Lifesciences was 34.48. The lowest was 12.88. And the median was 19.11.

BOM:540596's EV-to-EBITDA is ranked worse than
64.48% of 715 companies
in the Drug Manufacturers industry
Industry Median: 14.57 vs BOM:540596: 19.08

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), Eris Lifesciences's stock price is ₹878.40. Eris Lifesciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹28.790. Therefore, Eris Lifesciences's PE Ratio for today is 30.51.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Eris Lifesciences EV-to-EBITDA Historical Data

The historical data trend for Eris Lifesciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eris Lifesciences EV-to-EBITDA Chart

Eris Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.81 18.49 18.08 15.69 19.26

Eris Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.69 16.18 20.47 18.91 19.26

Competitive Comparison of Eris Lifesciences's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eris Lifesciences's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Eris Lifesciences's EV-to-EBITDA falls into.



Eris Lifesciences EV-to-EBITDA Calculation

Eris Lifesciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=133292.690/6986.45
=19.08

Eris Lifesciences's current Enterprise Value is ₹133,293 Mil.
Eris Lifesciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6,986 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eris Lifesciences  (BOM:540596) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Eris Lifesciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=878.40/28.790
=30.51

Eris Lifesciences's share price for today is ₹878.40.
Eris Lifesciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹28.790.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Eris Lifesciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Eris Lifesciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Eris Lifesciences (BOM:540596) Business Description

Traded in Other Exchanges
Address
Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast.

Eris Lifesciences (BOM:540596) Headlines

No Headlines